The comprehensive and integrated proteogenomic characterization is a valuable resource for the development of early detection strategies and identifies several promising new targets for pancreatic ductal adenocarcinoma treatment and early diagnosis.
A clinical study evaluated by the FDA found that Paige Prostate improved detection of cancer on individual slide images by 7.3% on average when compared to pathologists’ unassisted reads for whole slide images of individual biopsies, with no impact on the read of benign slide images.
A deep learning AI system designed by German researchers can help analyze flow cytometry data from different machines and labs and aid clinicians with making blood cancer diagnoses even if they only have access to minimal bioinformatics resources.
The kit is optimized for challenging NGS applications including liquid biopsy, somatic variant testing and genome-wide association studies.
A genomic atlas of proteins found in the brain of Alzheimer’s disease patients has helped identify new targets for treating Alzheimer’s, Parkinson’s, ALS, and stroke; and 29 drugs, already approved by the FDA for other indications, could be used to target these conditions.
Clofazimine, which was discovered in 1954, is FDA approved and on the World Health Organization’s List of Essential Medicines. The drug’s utility for COVID-19 was initially identified by screening more than 12,000 drugs from the ReFRAME drug library.
Immunocore's tebentafusp is the first T-cell receptor and the first systemic therapy that shows a significant survival benefit for patients with metastatic uveal melanoma, according to results from a Phase III trial.
According to the draft, remdesivir had not reduced the presence of SARS-CoV-2 in the bloodstream of 158 patients treated with the antiviral candidate in the 237-patient trial and 18 patients were taken off the drug due to side effects.
Researchers from The University of Texas MD Anderson Cancer Center say that grouping epidermal growth factor receptor (EGFR) mutations by structure and function can help to better match non-small cell lung cancer (NSCLC) patients to the most promising treatments.
Researchers found that blocking the activity of IL-6 at the blood-brain barrier increased the lifespan of fruit flies with cancer by 45% and also found that after 21 days, 75% of cancer-carrying lab mice treated with an IL-6 receptor blocker were alive, versus only 25% of untreated mice.
Of the 13 loci identified so far by the team, two had higher frequencies among patients of East Asian or South Asian ancestry than in those of European ancestry, underscoring the importance of diversity in genetic datasets.
GenapSys’ sequencing system is about the size of an iPad, costs under $10,000, and is based on a proprietary direct electronic sequencing chip, which is intended to eliminate the need for cumbersome equipment.
Research highlights from ESMO21 included results from Phase III DESTINY-Breast03 trial (AZ, Daiichi Sankyo), Phase II KRYSTAL-1 lung cancer study (Mirati Therapeutics), Phase III CheckMate 649 (Bristol Myers Squibb), and the Phase III KEYNOTE-826 trial.
A new immunotherapy using modified cells targeting two different antigens was highly effective in a mouse model of human neuroblastoma, according to a study led by researchers from the UNC Lineberger Comprehensive Cancer Center and the UNC School of Medicine.
A specialized hydrogel can not only encapsulate and protect mRNA cancer vaccines from being broken down in the body, but can also target lymph nodes to activate immune cells, shows early stage research.
The researchers identified differences in DNA methylation (DNAm) that accurately predicted different stages of liver fibrosis in as many as 94% of patients with non-alcoholic fatty liver disease (NAFLD), according to the study published in the journal Clinical Epigenetics.
MIT researchers revealed that vaccinating against certain neoantigens can boost overall T-cell response by reawakening dormant T cell populations that target those proteins and help shrink tumors in mice.
The nanobodies, which bind tightly to the SARS-CoV-2 virus, neutralizing it in cell culture, could provide a cheaper and easier to use alternative to human antibodies taken from patients who have recovered from COVID-19.
AI-based cancer imaging diagnostics have improved enormously over the last few years, with some programs already in use in the clinic, but researchers advise caution with more widespread rollout until more large-scale testing is completed.
U.S. researchers have developed an antiviral candidate drug targeting iron-sulfur clusters needed for SARS-CoV-2 RNA replicase to function properly and for the virus to reproduce successfully.
A new genomics program in South Carolina will enroll 100,000 volunteers over 4 years who will undergo exome testing to provide useful health information to the patients and their clinicians from the start, while also contributing to medical research.
Disruption of the mechanism leads to unrestricted gene transcription and is implicated in cancer, say the scientists. The study points to new opportunities for therapeutic intervention by demonstrating the anti-cancer effect of a new combination treatment in preclinical models of solid and hematopoietic malignancies.
Researchers at the Baylor College of Medicine report that they have found that microbes in the gut may contribute to certain symptoms associated with complex neurological disorders, which also suggests that microbe-inspired therapies may one day help to treat them.
Mitochondrial DNA fragments in the blood are a trigger for inflammation in people with sickle cell disease, suggests new research. The red blood cells of people with this chronic condition seem to accumulate mitochondria, which are absent from healthy blood cells. When these organelles break up their DNA is also broken up and found circulating in the blood.
An innovative bioinformatics approach developed at MIT and the Institute Pasteur allows genomes to be assembled within minutes on a standard desktop computer, a process that normally takes many hours and uses high amounts of computing power.